Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Friday, May 15, 2026

Snapshot: May 15, 2026 · 6:00 PM 100 stocks analyzed

Strong Down Day

Fri, May 15, 2026 Broad Selloff High

Broad selloff punishes tech and small-caps sharply while wild single-stock moves create pockets of extreme volatility, with Russell 2000 down 2.44% and VIX spiking 6.78%.

60% S&P 500 fell 1.23% with Russell 2000 leading the decline at -2.44%, signaling broad-based selling pressure across equities as small-cap weakness outpaced large-cap losses. NASDAQ dropped 1.54% with Technology commanding 31% of losers, including major declines from earnings misses and capital raises that spooked investors.
25% High dispersion dominated the tape as 50 gainers averaged +34.7% (led by HCWB's 262% surge on preclinical biotech news and PIII's 180% jump on earnings beat) while 50 losers averaged -25.9%, with WOK plunging 49.2% and LNZA down 43% on dilutive offering. The extreme spread between winners and losers created a stock-pickers' battleground despite the uniform selloff backdrop.
15% VIX spiked 6.78% signaling fear creeping back into the market, while persistent weakness in streaks like WOK and SBFM (3 consecutive days of losses) and Financial Services joining Technology as co-equal 31% losers underscored rotation and sector pain. Five debutants resurged into gainers on news-driven catalysts, contrasting sharply with the broader macro deterioration.

Technology drove 31% of losers 5 names returned after long absences QUCY · 3-day gainers streak WOK · 3-day losers streak HCWB — first appearance SLE — first appearance

Market Regime

Fri, May 15, 2026 Neutral conf: high macro · prototype

Neutral −100 … +100 · + tailwind / − headwind

VIX18.4 p67 Drawdown-1.2% Held1d · nascent SinceMay 15

Top drivers: S&P vs 50d avg ▲ VIX percentile ▼ Small-cap leadership ▼

processId: history-market-regime

Market Indexes

Fri, May 15, 2026 4

S&P 500

7,409.18

−92.06

-1.23%

NASDAQ Composite

26,225.14

−410.08

-1.54%

Russell 2000

2,793.30

−69.79

-2.44%

VIX

18.43

+1.17

+6.78%

Biggest Gainers

Fri, May 15, 2026 50

HCWB

HCW Biologics Inc.Healthcare

$1.22+$0.88

+262.0%

NASDAQ · Mkt cap $3.7 M

HCW Biologics surged 262% following announcement that its lead candidate HCW11-040 prevents bronchopulmonary dysplasia in preclinical studies and Q1 2026 business highlights disclosure, signaling potential clinical progress in a rare pediatric indication.

Two positive catalysts arrived within hours on May 14th. First, the company disclosed IND-enabling study results showing HCW11-040 (a pembrolizumab-based fusion immunotherapeutic) prevents bronchopulmonary dysplasia, a rare pediatric lung disease affecting premature infants. This preclinical validation of a novel mechanism represents material progress for a clinical-stage biotech. Second, concurrent Q1 2026 earnings and business highlights were released, though the full details were truncated in the headline. For early-stage biopharmaceutical companies with small market caps, positive preclinical data combined with operational updates can trigger outsized percentage moves, especially if prior sentiment was depressed. The stock's rank as 1 gainer and the 262% jump suggest this announcement reversed significant bearish positioning or broke through a psychological price floor.

PIII

P3 Health Partners Inc.Healthcare

$11.29+$7.26

+180.1%

NASDAQ · Mkt cap $1.8 B

P3 Health Partners crushed Q1 2026 earnings expectations, raised full-year guidance, and strengthened its balance sheet through strategic debt conversion, triggering a 180% single-day surge on heavy trading volume.

The headlines establish that P3 reported robust Q1 results that surpassed expectations and announced a raised full-year outlook alongside a balance sheet enhancement via debt conversion. These are classic positive catalysts for equity gains, especially in healthcare services where margin and guidance improvements tend to drive multiple expansion. The magnitude of the move—180%—is extreme and suggests either that the beat was exceptionally large relative to prior consensus, that the stock was heavily shorted or thinly traded, or that market sentiment toward the company had been deeply depressed before this earnings release. Without access to the actual earnings numbers, consensus estimates, or trading volumes, it is not possible to isolate whether the move reflects fundamental repricing or technical dynamics such as short covering. The debt-to-equity conversion is notable for balance sheet health but does not directly create economic value.

MRNO

Murano Global Investments PLC Ordinary SharesReal Estate

$0.57+$0.27

+94.2%

NASDAQ · Mkt cap $19 M

No news headlines were found in the last 48 hours, so the 94% gain cannot be attributed to a disclosed corporate event; the move may reflect technical trading, sector momentum, short covering, or an untracked announcement.

The absence of any news in the Yahoo Finance RSS feed for the prior 48 hours is notable given the magnitude of the gain. MRNO is a small-cap stock trading at $0.57, which makes it susceptible to several non-news-driven catalysts. Penny stocks and micro-cap securities often experience sharp intraday moves due to technical factors such as thin liquidity, short squeezes, momentum-driven retail trading, or delayed disclosure of corporate developments not yet picked up by major news aggregators. It is also possible that a material event (earnings, guidance, management announcement) was released but has not yet propagated to the primary news feed monitored. Without either headlines or structural information about MRNO's business or shareholder base, attributing causation is speculative.

AUUD

Auddia Inc.Technology

$1.96+$0.74

+60.7%

NASDAQ · Mkt cap $5.5 M

Auddia announced an S-4 merger submission with Thramann Holdings to create McCarthy Finney, a unified AI platform combining four AI-enabled businesses, which likely triggered the 60% gain on investor optimism around the consolidation and AI positioning.

The headline establishes a concrete M&A catalyst: Auddia has submitted an S-4 registration statement for merger with Thramann Holdings, creating an entity called McCarthy Finney that will operate on a shared agentic AI platform (MF-OS). The news highlights that the combined company will integrate four AI-enabled businesses and that prior $12 million financing is expected to satisfy closing cash requirements. This is a material corporate action that typically signals growth through consolidation and strategic focus on AI, a sector with elevated investor appetite in 2026. The 60% single-day move is consistent with market enthusiasm for both M&A closures and AI platform consolidation plays. However, the headline is truncated mid-sentence, so full context around valuation impact, shareholder vote timing, or closing conditions is not available.

PTIX

Protagenic Therapeutics, Inc.Healthcare

$0.65+$0.22

+51.1%

NASDAQ · Mkt cap $652 K

No news headlines were found in the last 48 hours, so the 51% gain likely stems from technical factors, delayed news processing, or an untracked catalyst specific to this small-cap biotech stock.

PTIX experienced a substantial single-day gain of 51%, ranking it among the day's top movers, yet no recent news headlines appear in the Yahoo Finance feed covering the prior 48 hours. This disconnect suggests the move was not driven by a major announced event like clinical trial results, regulatory approval, or earnings. For a small-cap biotech company trading at $0.65, possible explanations include technical rebound from oversold conditions, accumulation by retail traders, short covering, or a material announcement that has not yet been indexed by the news aggregator. Biotech stocks at this price tier are sensitive to speculative interest and can move sharply on limited catalysts or trader positioning. Without corroborating headlines, attributing the move to a specific fundamental event is not supported by available evidence.

SLE

Super League Enterprise, Inc.Communication Services

$6.04+$1.97

+48.4%

NASDAQ · Mkt cap $6.6 M

SLE surged 48.4% on May 15 following Q1 2026 earnings that beat revenue expectations by 3.55%, reported a loss smaller than forecast (earnings surprise +32.96%), and signaled improved operational momentum with a path to EBITDA profitability by year-end.

Super League Enterprise reported first-quarter results that delivered a positive earnings surprise of approximately 33% and topped revenue estimates by 3.55%. The company's press release emphasized a transition from corporate restructuring to operational execution, citing gross revenue growth, improved gross margin, and a strengthened cash position. Management also guided toward EBITDA profitability by the end of the fiscal year. For a micro-cap stock like SLE that has undergone restructuring, beating expectations on both profitability and revenue while articulating a credible path to cash-flow breakeven can trigger substantial relief buying and renewed investor confidence in the turnaround narrative. The 48% single-day jump aligns with the magnitude of surprise and the forward-looking positive guidance.

TRT

Trio-Tech InternationalTechnology

$20.05+$6.03

+43.0%

AMEX · Mkt cap $114 M

Trio-Tech reported 124% Q3 revenue growth driven by strong semiconductor reliability testing demand for AI and automotive applications, directly explaining the 43% single-day jump as investors responded to exceptional earnings growth.

The headline from May 14 reveals a clear catalyst: Trio-Tech announced quarterly revenue growth of 124%, substantially exceeding typical semiconductor industry growth rates. The company explicitly attributed this surge to elevated demand in two high-growth end-markets, AI and automotive, both of which have been major drivers of semiconductor equipment and testing services in 2025-2026. As a provider of semiconductor back-end solutions and reliability testing, Trio-Tech is positioned directly in the path of AI infrastructure buildout and electric vehicle proliferation. The magnitude of the revenue beat combined with explicit demand commentary from two of the hottest sectors in technology likely triggered broad institutional buying and short covering. The stock's rank as the seventh largest gainer on May 15 suggests this was a market-wide recognized catalyst rather than a niche discovery.

ERNA

Ernexa Therapeutics Inc.Healthcare

$13.63+$4.07

+42.6%

NASDAQ · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 42.57% jump in ERNA cannot be attributed to a specific disclosed event; the move likely reflects either delayed market reaction to older news, technical factors, or undisclosed company developments.

The absence of news headlines in the Yahoo Finance RSS feed over the last two days makes it impossible to pinpoint a definitive catalyst for ERNA's significant 42.57% gain. For a small-cap biotech or therapeutic company like Ernexa, large single-day moves typically correlate with clinical trial results, FDA decisions, partnership announcements, or earnings surprises. The ranking as the eighth biggest gainer suggests this was a broadly visible move, which would normally accompany material news. Possible explanations include a press release or news item not yet captured in the RSS feed, market reaction to older clinical data or regulatory developments, short covering, or technical momentum in a low-liquidity name. Without access to company filings, press releases, or other news sources beyond the provided headlines, the underlying cause remains speculative.

SKK

SKK Holdings LimitedIndustrials

$4.77+$1.38

+40.7%

NASDAQ · Mkt cap $14 M

No news headlines appeared in the last 48 hours for SKK Holdings, so the 40.71% gain cannot be attributed to a disclosed company announcement or event. The spike likely reflects technical trading, delayed reaction to prior news, or market rumors not yet indexed by Yahoo Finance.

The absence of any news in the last 48 hours is notable given the stock's ninth-place ranking among daily gainers. A 40.71% one-day move on a NASDAQ-listed security would typically warrant immediate press coverage if driven by material corporate events such as earnings, guidance, product approvals, or M&A. This gap suggests either that the catalyst is technical in nature (short squeeze, options expiration pinning, algorithmic rebalancing, or retail volume spike), that relevant news was released outside the monitored news feed, or that the move is driven by market sentiment not yet formalized into public announcements. Without access to SKK's recent earnings dates, insider ownership structure, short interest levels, or float characteristics, assigning high confidence to any specific mechanism is inappropriate.

EXPI

eXp World Holdings, Inc.Real Estate

$6.74+$1.82

+37.0%

NASDAQ · Mkt cap $677 M

eXp World reported Q1 2026 revenue of $1.01 billion, beating Wall Street expectations with 5.3% year-on-year growth and optimistic guidance, triggering the 37% rally on the day of earnings release.

The stock's 36.99% gain on May 15 aligns with the timing of eXp World's Q1 earnings announcement that same day. The headline explicitly states revenue came in ahead of Wall Street expectations at $1.01 billion with year-on-year growth of 5.3 percent. The article references optimistic guidance for the next quarter, though the full details are truncated. The company also appears to be executing on multi-model expansion, productivity gains, and franchise integration initiatives. A second headline references analyst estimates following the first-quarter report, suggesting broad broker commentary. The magnitude of the move is substantial, suggesting the beat and forward guidance resonated strongly with investors, possibly indicating the results exceeded not just consensus estimates but were viewed as a meaningful inflection point for the real estate technology company.

BOT

RoboStrategy, Inc. Common StockFinancial Services

$36.01+$8.91

+32.9%

NASDAQ · Mkt cap $665 M

RoboStrategy announced a $2 billion committed equity facility from Roth Principal Investments on May 15, which directly funded a major rally of 32.88% as the largest intraday gainer, signaling strong capital support for growth initiatives in the robotics and AI fund space.

The headline establishes that RoboStrategy entered into a committed equity facility of up to $2 billion on the announcement date itself. This is a material capital event for an investment fund focused on robotics and physical AI exposure. A $2 billion committed facility represents substantial financial firepower that would enable expanded positions, improved liquidity management, or accelerated strategic initiatives. For a dedicated investment vehicle, access to large-scale committed capital typically signals confidence from a major financial backer and removes near-term funding constraints. The timing alignment between the announcement and the 32.88% single-day move, combined with BOT's rank as the 11th biggest gainer on the day, strongly suggests market participants viewed this facility as significantly positive news for future operations and capital deployment capacity.

JDZG

JIADE LimitedConsumer Defensive

$2.21+$0.54

+32.3%

NASDAQ · Mkt cap $23 M

No news headlines were found in the last 48 hours, so the 32% gain on JDZG is unexplained by public company announcements; the move likely reflects technical trading, delayed reporting, or unconfirmed rumors.

The absence of any news in the Yahoo Finance RSS feed over the past two days means we cannot point to a specific catalyst such as earnings, guidance, contract wins, or regulatory approvals. A 32% single-day jump on a micro-cap NASDAQ stock like JDZG typically occurs in response to one of several types of events: a major company announcement not yet indexed by the feed, short covering or squeeze activity driven by low float and high short interest, insider buying or significant institutional accumulation, or retail trading momentum driven by social media or unconfirmed rumors. Without access to press releases, SEC filings, social media sentiment, or short interest data, we cannot distinguish between these possibilities. The lack of news coverage itself is notable and suggests either the catalyst is very recent, unofficial, or the stock is moving on technical or speculative factors rather than fundamental developments.

GDTC

CytoMed Therapeutics LimitedHealthcare

$1.16+$0.28

+31.8%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours to explain GDTC's 31.79% gain, so the driver remains unclear; the move may reflect technical activity, delayed announcements, or sector sentiment in biotech.

No headlines were published in the last 48 hours according to the Yahoo Finance RSS feed provided, so there is no news-grounded explanation for this 31.79% intraday jump. For a small-cap biotech stock like CytoMed Therapeutics, typical catalysts include clinical trial results, FDA decisions, partnership announcements, or changes in guidance. The absence of reported news suggests either that a material event occurred but was not yet indexed by the feed, that the move reflects technical or options-driven factors, or that market sentiment shifted on sector-wide or company-specific information not yet public. Without additional context, attributing this gain to a specific catalyst would be speculation.

TDIC

Dreamland Limited Class A Ordinary SharesCommunication Services

$1.04+$0.24

+30.0%

NASDAQ · Mkt cap $4.0 M

No news headlines were found in the last 48 hours, so the 30% gain cannot be attributed to a specific announced catalyst. The move likely reflects technical trading, delayed news absorption, or unconfirmed market rumors.

TDIC experienced a significant 30% single-day jump to rank among the top 14 gainers on NASDAQ, yet no news events appear in the available feed for the prior 48 hours. This disconnect suggests the move was not driven by a major announced earnings beat, regulatory approval, merger, or guidance change. For a micro-cap or thinly traded security like this, large single-day moves can result from several sources: technical factors such as short covering or momentum buying in low-liquidity names, delayed or embargoed news that markets learned about through other channels before official release, analyst upgrades not yet captured in the RSS feed, or unverified rumors circulating among retail traders. Without additional context on TDIC's business, short interest, or institutional ownership, it is impossible to determine which of these mechanisms drove the move.

AIFU

AIFU Inc.Financial Services

$2.31+$0.52

+29.1%

NASDAQ · Mkt cap $74 M

No news headlines were published in the last 48 hours, so the 29% gain on May 15 cannot be directly attributed to a disclosed event. The move likely reflects either a delayed market reaction to earlier news, technical trading, or an undisclosed catalyst.

The absence of recent news makes it difficult to pinpoint a specific cause for AIFU's sharp 29% single-day gain. For a small-cap or micro-cap stock like AIFU trading near $2.31, such moves can be driven by several common mechanisms: a delayed market reaction to news released more than 48 hours prior, short covering or technical breakouts, sector rotation into AI-related equities (given the ticker references AI), insider buying, or a pending announcement not yet reflected in the news feed. Without access to headlines beyond the 48-hour window or real-time news flow, we cannot rule out any of these drivers. The fact that AIFU ranked 15 in daily gainers suggests broad market attention, but that alone does not establish causation.

XRTX

XORTX Therapeutics Inc.Healthcare

$2.59+$0.58

+28.9%

NASDAQ · Mkt cap $3.5 M

XORTX announced a $5 million public offering on May 14, which likely sparked the 28.86% gain as investors reacted positively to the capital raise or anticipated dilution expectations were already priced in at lower levels.

The headline confirms XORTX announced a US$5 million public offering on May 14, 2026. For a small-cap clinical-stage pharmaceutical company, a capital raise typically signals the company has secured near-term runway to advance its pipeline. The magnitude of the gain suggests the market viewed this announcement favorably, which could reflect relief that funding was secured without worse-than-expected dilution, confidence in the company's clinical progress, or simply that the stock had been oversold prior to the announcement. Without additional detail on the offering terms, pricing, or any concurrent clinical updates, we cannot confirm whether the jump stems primarily from the capital event itself or from other concurrent positive developments in the company's pipeline or business.

STAK

STAK Inc. Ordinary SharesEnergy

$1.12+$0.24

+27.3%

NASDAQ · Mkt cap $29 M

STAK rebounded sharply after a 39% after-hours plunge on May 14th, likely as investors reassessed the company's earnings miss and concluded the sell-off was overdone given the underlying revenue growth story.

On May 13-14, STAK reported first-half 2026 financial results showing revenue growth but declining profitability, triggering a severe 39% after-hours sell-off on May 14th. The May 15th bounce of 27.27% appears to be a reversal or stabilization trade, potentially driven by technical oversold conditions, short covering, or value investors stepping in after the sharp decline. The headline explicitly states the stock "plunges" despite revenue growth, which signals the market initially overreacted to the profitability miss. The subsequent gain suggests either that the sell-off was deemed excessive relative to the positive revenue trajectory, or that intraday trading dynamics corrected an emotion-driven rout. Without additional news between May 14th close and May 15th, this looks like a typical volatility reversal after an earnings-driven washout rather than a new positive catalyst.

GCTS

GCT Semiconductor Holding, Inc.Technology

$1.83+$0.39

+27.1%

NYSE · Mkt cap $182 M

GCT Semiconductor surged 27% after reporting its first quarter of revenue growth following two years of consecutive declines, signaling a potential turnaround in the struggling chipmaker's business trajectory.

The headline explicitly states that GCTS reported year-over-year revenue growth in Q1 2026 and sequential growth into Q2, marking the company's first expansion after a two-year contraction period. For a semiconductor company that has been declining, returning to revenue growth is a significant inflection point that typically triggers investor re-rating and short covering. The stock's 27% single-day jump aligns with a classic recovery narrative: after sustained losses, proof of stabilization and revenue acceleration attracts both fundamental investors reassessing the turnaround thesis and traders closing short positions. The timing of the announcement on May 14 directly precedes the May 15 price action, establishing a clear causal link between the earnings news and the rally.

HYLN

Hyliion Holdings Corp.Consumer Cyclical

$4.67+$0.98

+26.6%

AMEX · Mkt cap $654 M

Hyliion reported a four-fold Q1 2026 revenue increase and announced new strategic partnerships on May 13, driving a +26.56% single-day rally as investors responded to material operational progress despite ongoing profitability challenges.

The timing and magnitude of the move align directly with the Q1 2026 earnings call held on May 13, highlighted by a four-fold revenue surge and new strategic partnerships. These represent concrete operational milestones for a hydrogen-electric powertrain company attempting to move from commercialization phase to revenue scaling. The headlines acknowledge ongoing financial challenges and commercialization hurdles, so the market is not pricing in profitability yet, but rather rewarding evidence of traction in a capital-intensive, high-growth sector. A 26.56% single-day move following an earnings call with material positive operational metrics is consistent with a stock that has been depressed and is now getting validation of its business model at scale. The inclusion in a "growth companies with high insider ownership" article on May 14 likely reflects post-earnings momentum rather than catalyzing it.

FIGG

Leverage Shares 2x Long FIG Daily ETF

$25.16+$5.15

+25.7%

NASDAQ

No news headlines were found in the last 48 hours; however, FIGG is a 2x leveraged long ETF on Figueroa Resource Corp (FIG), so a 25.74% jump most likely reflects a sharp rally in the underlying stock, which would be amplified roughly 2x by the leverage structure.

No recent news appeared in the Yahoo Finance RSS feed for the past 48 hours, so there is no direct headline-based explanation available. However, FIGG's structure as a 2x daily leverage ETF means it is designed to deliver approximately twice the daily return of its underlying asset. A 25.74% move in FIGG would be consistent with roughly a 12-13% move in the underlying FIG stock on a single day. This kind of magnitude typically requires a significant catalyst—such as earnings, a major contract announcement, a strategic investment, insider buying, or sector-wide momentum. Without access to FIG-specific news or market data for May 15, 2026, the specific trigger cannot be identified, but the move itself is structurally explained by the leverage amplifying whatever gain occurred in the underlying equity.

CELG-RI

Bristol-Myers Squibb Company Ce

$0.13+$0.03

+24.6%

JXG

JX Luxventure LimitedConsumer Cyclical

$6.53+$1.26

+24.0%

NASDAQ · Mkt cap $94 M

JX Luxventure reported a 66% revenue surge to $83.0 million in fiscal year 2025 results, which directly triggered the 23.96% stock jump as investors responded to strong top-line growth in the duty-free and cross-border consumer goods sector.

The company announced fiscal year 2025 financial results showing substantial revenue growth of 66% year-over-year, reaching $83.0 million. This represents a material earnings beat relative to what appears to be market expectations, given the magnitude of the stock's intraday response. JX Luxventure operates in wholesale trade, specifically duty-free and cross-border consumer goods distribution, which has benefited from post-pandemic normalization in luxury goods consumption and cross-border commerce. The headline indicates this is a full fiscal year result announcement rather than a warning or disappointment. No negative guidance revisions or headwinds are mentioned in the available news snippet. The 23.96% gain ranking the stock as the 22nd biggest gainer of the day is consistent with a company of this market capitalization receiving a significant positive earnings surprise or re-rating based on accelerating revenue trajectory.

SEGG

Sports Entertainment Gaming Global CorporationConsumer Cyclical

$1.87+$0.36

+23.8%

NASDAQ · Mkt cap $8.4 M

No news headlines were found in the last 48 hours, so the 23.84% gain cannot be attributed to a specific reported event. The jump may reflect technical trading, delayed news dissemination, or market speculation in this small-cap gaming stock.

Despite a robust single-day gain that ranked SEGG 23rd among all NASDAQ gainers, no recent news headlines are available to explain the move. This absence of reported catalyst is notable for a stock with such significant upward momentum. Small-cap and gaming-sector stocks are particularly sensitive to technical factors, including short covering, options expiration dynamics, and retail momentum trading. Additionally, news may have been released through channels not captured by Yahoo Finance RSS within the 48-hour window, or the market reaction may have been delayed. Without access to SEC filings, press releases, or alternative news sources, the underlying cause remains unconfirmed. The most likely categories are technical rebalancing, insider activity becoming public, or sector-specific sentiment shifts in gaming entertainment.

SKYQ

Sky Quarry Inc.Energy

$3.07+$0.58

+23.3%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 23.29% gain likely reflects a technical bounce, delayed market reaction to an older announcement, or an undisclosed catalyst not yet reported through major news channels.

Sky Quarry Inc. (SKYQ) jumped 23.29% to rank among the day's top 25 gainers, yet the search returned zero news headlines from Yahoo Finance in the preceding 48 hours. This disconnect suggests either a latent market reaction to older information, a technical or sentiment-driven move in a lower-liquidity stock, or an announcement disseminated through channels not yet indexed by major RSS feeds. Micro-cap and small-cap stocks like SKYQ can exhibit outsized moves on thin volume or based on social media momentum, insider activity, or delayed earnings/guidance releases that haven't yet reached mainstream coverage. Without corroborating news, attributing this move to any specific catalyst would be speculation rather than analysis.

AIB

BlockchAIn Digital Infrastructure, Inc.Technology

$1.44+$0.27

+23.1%

SEDG

SolarEdge Technologies, Inc.Technology

$61.76+$11.52

+22.9%

NASDAQ · Mkt cap $2.1 B

SolarEdge rallied 22.9% on Thursday-Friday following Q1 earnings that showed narrower losses, new CFO appointment, a legal settlement, and strong second-quarter revenue guidance of $325-355 million amid investor positioning ahead of a tax credit deadline.

SolarEdge's two-day surge of over 40% was driven by multiple catalysts announced on or before May 15. First-quarter 2026 results showed the company reduced net losses to $57.37 million on $310.5 million in sales, demonstrating operational improvement. Management changes (new CFO) and resolution of a legal matter also signaled reduced uncertainty. The most significant driver appears to be forward guidance: Q2 revenue guidance of $325-355 million suggested accelerating demand. This was amplified by investor positioning ahead of a tax credit deadline, which created urgency for solar adoption. The sector-wide rally (Enphase up 11% same day) indicates broad solar tailwinds, though SolarEdge's specific guidance and loss narrowing outperformed competitors like Canadian Solar, which fell 11% despite a narrower-than-expected loss.

NPT

Texxon Holding Limited Ordinary sharesConsumer Cyclical

$1.48+$0.27

+22.3%

NASDAQ · Mkt cap $79 M

No news headlines were found in the last 48 hours for NPT, so the 22.31% gain likely reflects technical trading, delayed news pickup, or sector momentum rather than a company-specific catalyst.

The absence of any recent headlines in the provided news feed makes it impossible to identify a specific fundamental catalyst for NPT's strong gain. However, a 22% single-day move in a stock trading near $1.50 suggests several common mechanisms: short covering or short squeeze dynamics (micro-cap stocks are susceptible), technical chart breakout triggering algorithmic or retail buying, delayed coverage of an older announcement not yet indexed in the 48-hour window, sector rotation into a category NPT belongs to, or speculative momentum in lower-priced NASDAQ names. Without access to the company's recent earnings, guidance, partnerships, regulatory actions, or insider trades, we cannot distinguish among these possibilities. The stock's low absolute price and rank as a top gainer suggest retail interest and low float dynamics may be at play.

GDXD

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

$39.73+$7.06

+21.6%

AMEX

No news headlines were found in the last 48 hours, but GDXD is a -3X inverse leveraged ETN on gold miners, so a 21.61% gain likely reflects a sharp decline in the underlying gold mining sector or gold prices.

No recent news headlines are available to directly explain the move. However, GDXD's structure is critical context: it is a -3X inverse leveraged ETN, meaning it moves opposite to and amplifies declines in gold mining stocks by a factor of three. A 21.61% gain in GDXD would be consistent with approximately a 7% or larger one-day drop in the underlying gold miners index or gold prices themselves. The catalyst would likely be macroeconomic—such as a sharp rise in US Treasury yields, a stronger US dollar, hawkish central bank commentary, or a significant repricing of inflation expectations—all of which typically depress gold demand and mining equities. Without named headlines, the cause cannot be pinpointed to a specific event, but the move fits the typical behavior of this inverse leveraged security during a broad-based selloff in commodities or risk assets.

LOBO

Lobo EV Technologies Ltd.Consumer Cyclical

$0.75+$0.13

+20.9%

NASDAQ · Mkt cap $9.3 M

Lobo EV Technologies surged over 33% in after-hours trading on 2026-05-14, recovering from an earlier 8.43% intraday decline, though the headline was cut off before disclosing the specific catalyst.

The headline indicates a sharp 33.70% after-hours jump from $0.52 to $0.69, with intraday weakness followed by a strong recovery. The news snippet from Benzinga Pro mentions Lobo Technologies as a China-based EV manufacturer but does not complete the explanation of what triggered the surge. The opening phrase "According to Benzinga Pro, the stock of the China-based manufacturer and seller of ele..." cuts off mid-sentence, leaving the actual catalyst unidentified. Possible drivers for a micro-cap EV stock of this magnitude could include a strategic partnership announcement, product launch, financing round, or short-squeeze activity, but these remain inference rather than fact. The 20.93% further gain on 2026-05-15 suggests momentum continuation, but without the full headline content, the root cause remains unknown.

GETY

Getty Images Holdings, Inc.Communication Services

$0.86+$0.15

+20.7%

NYSE · Mkt cap $111 M

Getty Images surged 20.66% after the UK regulator conditionally approved its merger with Shutterstock, removing a major regulatory hurdle despite the requirement that Shutterstock divest its editorial business first.

The stock's strong gain follows conditional approval from UK authorities for the Shutterstock-Getty Images merger announced on 2026-05-15. This represents a significant de-risking of the transaction, which had faced regulatory scrutiny. While the approval is conditional on Shutterstock selling its editorial division, the fact that regulators cleared the deal structure suggests the merger will likely proceed. The timing of the 20.66% jump directly correlates with this news. Context matters here: earlier the same day, Getty reported Q1 earnings that disappointed on revenue growth (1.1% YoY), yet the merger news appears to have outweighed earnings weakness. The market is likely pricing in merger value and the prospect of combined operations, seeing regulatory approval as the key gate that needed clearing.

IPST

IP Strategy Holdings, Inc.Consumer Defensive

$9.69+$1.63

+20.2%

CAEP

Cantor Equity Partners III, Inc. Class A Ordinary SharesFinancial Services

$15.00+$2.51

+20.1%

BKYI

BIO-key International, Inc.Industrials

$4.15+$0.69

+19.9%

NASDAQ · Mkt cap $4.3 M

No news headlines were found in the last 48 hours, so the 19.94% gain likely reflects a delayed market reaction to earlier news, technical trading, or untracked developments.

BIO-key International is a small-cap biometric security company, the kind of firm that often experiences volatile intraday moves on modest volume. With zero headlines in the most recent 48-hour window, the jump cannot be traced to a specific catalyst like earnings, FDA clearance, or contract news. For stocks in this sector and market cap range, such moves typically stem from one of several unstated factors: a delayed market reaction to older news not captured in this feed, short covering in a thinly traded name, technical breakout above resistance, investor rotation into small-cap or biotech plays, or unverified rumors circulating on social media or message boards. Without access to trading volume, short interest, or technical charts, it is impossible to determine which explanation applies.

LZMH

LZ Technology Holdings Limited Class B Ordinary SharesTechnology

$0.10+$0.02

+19.4%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 19.36% gain in LZMH is likely driven by technical trading, short covering, or unindexed corporate developments not yet reflected in major financial media.

The absence of recent news makes direct attribution impossible. LZMH is a thinly traded microcap stock trading at $0.10, a profile typical of penny stocks where small absolute dollar volumes can produce outsized percentage moves. The gain could reflect several non-news drivers: short-squeeze dynamics if the stock had heavy short interest, retail momentum trading, delayed disclosure of corporate events (earnings, partnerships, or filings not yet syndicated to major news feeds), or pure technical mean reversion after an earlier decline. Micro-cap stocks in this price range often move on rumors, social media discussion, or trading algorithms rather than institutional news flow, making causation difficult to establish without additional research into volume patterns, short interest, or regulatory filings.

IONZ

Daily Target 2X Short IONQ ETF

$4.03+$0.64

+18.9%

NASDAQ

No recent news headlines were found, but IONZ is a 2X inverse leveraged ETF tracking IonQ, so it gains when IonQ stock falls sharply; the +18.88% jump likely reflects a significant drop in the underlying IONQ stock price over the last 48 hours.

IONZ is a Daily Target 2X Short ETF, meaning it is designed to move roughly double the inverse direction of IonQ's stock price on a daily basis. With no news headlines provided from the past 48 hours, we cannot identify a specific catalyst from the information given. However, the structure of this security itself provides a clear explanation: a substantial decline in IONQ stock would mechanically produce a gain in IONZ. The move is consistent with IONQ having fallen approximately 9-10 percent, which would translate to roughly an 18-20 percent gain in a 2X inverse instrument. The lack of news does not mean no catalyst occurred; IonQ-specific developments, quantum computing sector weakness, broader market losses, or technical selling pressure could all have driven the underlying move, but those details are simply not present in the available news feed.

BWEN

Broadwind, Inc.Industrials

$4.52+$0.70

+18.3%

NASDAQ · Mkt cap $115 M

No news headlines were found in the last 48 hours, so the 18.32% gain likely stems from technical factors, delayed reporting of an announcement, or market sentiment shift specific to the industrial/renewable energy sector.

Broadwind is a diversified industrial manufacturer with exposure to renewable energy components and infrastructure services. The absence of any news in the provided headlines over the last 48 hours means the jump cannot be attributed to a disclosed earnings beat, contract win, or guidance change. However, a move of this magnitude in a stock ranked 36th among daily gainers suggests either a meaningful catalyst existed but has not yet been picked up by Yahoo Finance RSS feeds, or the move is driven by technical trading activity such as short covering, options-related hedging, sector rotation into renewable energy plays, or intraday momentum. Without access to the specific catalyst, the most honest assessment is that we lack sufficient visibility into the true driver.

TURB

Turbo Energy, S.A. American Depositary SharesTechnology

$1.36+$0.21

+18.3%

NASDAQ · Mkt cap $15 M

No news headlines were found in the last 48 hours, so the 18.26% gain on TURB is unexplained by reported announcements. The move likely reflects technical trading, delayed news, or market sentiment shifts in the micro-cap energy sector.

The absence of any Yahoo Finance headlines in the 48-hour window prior to this significant single-day gain makes it impossible to identify a specific fundamental catalyst from published sources. TURB is a micro-cap ADR with limited analyst coverage, which is typical of securities prone to technical moves, short covering, and rumors that may not appear in mainstream financial news feeds immediately. Possible explanations within the inference category include: a delayed or embargoed announcement that has not yet propagated to major news wires, a short squeeze driven by options expiration or technical support levels, or sector-wide optimism in renewable or energy transition narratives that may have driven multiple names higher without company-specific news. Without corroborating headlines or insider data, we cannot distinguish between these scenarios.

VSTD

Vestand Inc.Consumer Cyclical

$0.59+$0.09

+18.2%

NASDAQ · Mkt cap $15 K

No news headlines were found in the last 48 hours to explain VSTD's 18.24% gain, suggesting the move was likely driven by technical factors, retail trading activity, or unindexed news.

The absence of any Yahoo Finance headlines in the past two days means we cannot identify a specific corporate event, earnings release, FDA decision, or strategic announcement as the driver of this 18-cent move on a penny stock. VSTD's low price point ($0.59) and position as the 38th biggest gainer suggest it is a thinly traded micro-cap where price movements can be amplified by small volumes or momentum-driven retail interest. Penny stocks of this type often respond sharply to technical patterns, short covering, social media attention, or delayed news that may not immediately appear in major financial wire feeds. Without access to Level 2 data, trading volume metrics, or alternative news sources, we cannot isolate the specific catalyst.

JLHL

Julong Holding Limited Class A Ordinary SharesIndustrials

$23.26+$3.48

+17.6%

NASDAQ · Mkt cap $152 M

No news headlines were found in the last 48 hours for JLHL, so the 17.59% gain cannot be directly attributed to a disclosed announcement or event. The jump likely reflects technical trading, a delayed news release, or market speculation.

The absence of recent news coverage makes it difficult to pinpoint a specific catalyst for JLHL's strong performance today. A 17.59% single-day move on a NASDAQ-listed company typically warrants either a material announcement (earnings beat, contract win, regulatory approval, guidance raise) or significant technical activity (short squeeze, options-driven demand, index inclusion, or large institutional buying). Given that no such headlines appear in the last 48 hours, several scenarios are plausible. First, the news may have been released outside the Yahoo Finance RSS feed window or on a timing delay. Second, this could be a short-squeeze or technical breakout driven by option expiry, moving averages, or low float dynamics. Third, a rumor or social media catalyst that has not yet reached mainstream financial news could be driving retail interest. Without substantive headline support, the move remains unexplained by publicly disclosed fundamental or corporate events.

Sweetgreen, Inc.Consumer Cyclical

$8.09+$1.20

+17.4%

NYSE · Mkt cap $795 M

No news directly tied to SG's 17.4% jump was provided in the headlines; the catalyst remains unclear, though the move coincides with a critical analyst comment questioning the company's profitability.

The two headlines provided do not directly explain SG's surge. The McDonald's margin story is unrelated to Sweetgreen. The Jim Cramer piece, published on 2026-05-14, notes that Cramer discussed Sweetgreen among 20 stocks and mentions it "never made any money," which is a bearish characterization unlikely to drive a 17% gain the next day. This timing suggests either the headline excerpt is misleading about Cramer's stance (he may have recommended it despite profitability concerns), or the stock moved on an unrelated catalyst—possibly a market correction of oversold sentiment, a short squeeze, or an internal company announcement not captured in these two headlines. Without additional news from May 15th itself, the specific trigger is unknown.

FCUV

Focus Universal Inc.Technology

$0.84+$0.12

+17.4%

NASDAQ · Mkt cap $5.7 M

No news headlines were reported for FCUV in the last 48 hours, so the 17.39% gain likely reflects a technical bounce, retail interest, or undisclosed company event rather than a clearly identified catalyst.

Focus Universal Inc. is a micro-cap stock trading at $0.84, and the absence of recent news coverage makes it difficult to pinpoint the driver of today's 17.39% jump. This price tier and market cap typically attract retail traders and can be sensitive to social media discussions, short covering, or technical chart reversals that may not trigger immediate press releases. Possible explanations include: first, a technical rebound after earlier weakness, since stocks at this valuation often exhibit outsized volatility; second, an unannounced company development or internal news not yet picked up by Yahoo Finance's RSS feed. Without access to after-hours trading patterns, insider transactions, or options activity, attributing the move to any specific fundamental event would be speculative.

ZSL

ProShares - UltraShort Silver

$19.81+$2.94

+17.4%

BNZI

Banzai International, Inc.Technology

$7.66+$1.13

+17.3%

NASDAQ · Mkt cap $5.6 M

Banzai reported strong Q1 2026 results with an 80.7% gross margin and announced a non-binding letter of intent to acquire ConnectAndSell assets, likely driving the 17.30% gain as the market reacted positively to both solid financials and growth strategy.

The earnings headline shows Banzai achieved $2.7 million in Q1 revenue with an exceptional 80.7% gross profit margin, signaling operational efficiency and strong unit economics. The more material catalyst appears to be the announced non-binding letter of intent to acquire ConnectAndSell assets, which the company explicitly states is expected to increase revenue. For a small-cap company trading near $7.66, a strategic acquisition announcement that promises top-line growth combined with demonstrated profitability in the trailing quarter creates a compelling narrative. The second headline about Fluent appears unrelated to Banzai's move and likely included in the feed due to sector classification rather than direct relevance. The timing of both the earnings beat and M&A announcement on the same day likely amplified investor enthusiasm.

BIYA

Baiya International Group Inc. Ordinary SharesTechnology

$0.91+$0.13

+17.1%

NASDAQ · Mkt cap $71 M

No news headlines were found in the last 48 hours explaining the 17% gain in BIYA shares on May 15, 2026. The move likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or off-exchange news not captured by the available feeds.

The absence of any news headlines in the Yahoo Finance RSS feed over the last two days makes it impossible to identify a specific catalyst for the 17% jump. BIYA is a microcap trading below one dollar, which means the stock is prone to outsized volatility from small volumes and can be sensitive to technical factors like short covering, options expiration effects, or retail trading momentum. For stocks of this size and price range, moves can also be driven by delayed announcements that have not yet propagated through major financial news channels, or by activity on over-the-counter markets that may not be immediately reflected in headline feeds. Without corroborating news, the cause remains speculative across technical, algorithmic, or information-asymmetry categories.

COE

51Talk Online Education GroupConsumer Defensive

$28.75+$4.19

+17.1%

AMEX · Mkt cap $113 M

No news headlines were found in the last 48 hours, so the 17.06% gain cannot be attributed to a specific announced catalyst. The move likely reflects technical trading, market sentiment shifts, or an untracked rumor or announcement.

COE experienced a substantial single-day jump of 17.06% without any corresponding news coverage in the 48-hour window provided. This disconnect between price action and reported news makes identifying the direct cause difficult. For an online education stock like 51Talk, typical catalysts would include quarterly earnings surprises, user growth announcements, profitability milestones, or strategic partnerships. It is also possible that a material development occurred but has not yet been picked up by the Yahoo Finance RSS feed, or that the move reflects technical factors such as short covering, options-related hedging adjustments, or renewed retail interest in the name. Without headline confirmation, any specific cause remains speculative.

GPUS

Hyperscale Data, Inc.Industrials

$0.15+$0.02

+16.8%

AMEX · Mkt cap $31 M

Hyperscale Data announced a tender offer to repurchase up to $5 million of shares at $0.21 per share, a 40% premium to the closing price, signaling management confidence and likely driving the 16.80% intraday gain.

The company disclosed intent to launch a self-tender offer at $0.21 per share while the stock traded near $0.13–$0.15, representing substantial upside for tendering shareholders and a clear vote of confidence from management that the stock is undervalued. Share buybacks at a premium typically attract investor interest because they reduce share count, support the stock price mechanically, and signal insiders believe intrinsic value exceeds the current quote. For a micro-cap AI data center company like Hyperscale Data, the announcement of $5 million in capital deployment for buybacks is a material event. The timing of the announcement coinciding with the day's surge supports a direct causal link. No offsetting negative news appears in the recent headlines, making the tender offer the most plausible driver of the gain.

QUCY

Mainz Biomed N.V.Healthcare

$3.49+$0.49

+16.3%

NASDAQ · Mkt cap $15 M

Mainz Biomed (QUCY) jumped 16.33% following announcements of a new quantum-cyber platform targeting defense sectors and the appointment of a former Trump administration VA Secretary to its board, signaling expansion into high-growth government contracting markets.

The stock's strong gain aligns with two recent corporate developments. On 2026-05-15, the company launched quantum-cyber.ai targeting homeland security, autonomous drone, and quantum technology sectors, with emphasis on government demand tied to a reported $55 billion Trump administration autonomous warfare program. The prior day brought news that Peter O'Rourke Sr., a decorated military veteran and former Acting VA Secretary, joined the board, bringing defense and government expertise. Together, these announcements position the company to capture emerging defense technology spending and signal credibility with federal decision-makers. The timing and sector focus (autonomous systems, quantum tech, counter-UAS) align with elevated federal spending expectations, likely driving investor enthusiasm for growth potential in government contracting.

ORGN

Origin Materials, Inc.Basic Materials

$1.43+$0.20

+16.3%

NASDAQ · Mkt cap $3.7 M

No news headlines were found in the last 48 hours for ORGN, so the 16.26% gain likely reflects either a delayed market reaction to an earlier announcement, technical trading, or market rumors not yet captured in major news feeds.

Origin Materials is a materials science company focused on sustainable alternatives, and without recent news coverage available, the sharp single-day gain cannot be directly attributed to a specific corporate event. Companies in this sector are sensitive to several typical catalysts: updates on production capacity or commercialization milestones, partnership or contract announcements with major brands or suppliers, regulatory approvals for new materials, shifts in commodity pricing that affect competitive positioning, or technical buying if the stock had been heavily shorted. The 16.26% jump is substantial enough to suggest a material event rather than random drift, but without headline confirmation we cannot identify which category applies. It is also possible the news exists but has not yet propagated to the RSS feeds sampled, or a private discussion (earnings call, investor conference) occurred outside normal press release channels.

QBTZ

Defiance Daily Target 2X Short QBTS ETF

$14.00+$1.94

+16.1%

NASDAQ

No news headlines were found in the last 48 hours. QBTZ is a 2X short leveraged ETF, so a 16% gain likely reflects a sharp decline in its underlying index (QBTS) that got amplified by the 2X short structure.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for this move. However, QBTZ is structurally a daily leveraged inverse ETF tracking the Defiance QBTS ETF at 2X short exposure. This means the fund profits when QBTS falls, with returns amplified roughly double. A 16% single-day gain in QBTZ would imply approximately an 8% decline in QBTS or its underlying components. Without news on QBTS itself or its holdings, the most likely causes are broad market sell-offs, sector rotation within the QBTS mandate, technical unwinding of positions, or delayed market reaction to earlier announcements not captured in the current news feed. Leveraged inverse ETFs are also subject to tracking decay and can experience volatility spikes from rebalancing activity independent of underlying fundamentals.

GGRP

The Glimpse Group, Inc.Technology

$0.65+$0.09

+15.9%

NASDAQ · Mkt cap $20 M

Glimpse announced a $1.845 million investment round and a strategic pivot to become a "pureplay Physical AI company" with direct backing from its two largest shareholders and incoming executive leadership, triggering a 15.95% rally.

The two headlines from May 14-15 establish that Glimpse has undergone a significant corporate restructuring. The company is repositioning itself away from a generalized immersive technology platform toward a focused Physical AI strategy. The news explicitly mentions direct equity investment from the company's two largest shareholders, incoming board members, and executive changes, suggesting renewed confidence and capital commitment at the ownership level. The $1.845 million pricing announcement on May 15 follows the earlier announcement of the strategic shift and Q3 financial results. For a micro-cap stock trading at $0.65, a concrete capital raise combined with a clear strategic pivot and insider shareholder support typically triggers algorithmic buying and retail momentum. The rally rank of 50 largest gainer suggests broad market participation in the move, not an isolated data point.

Biggest Losers

Fri, May 15, 2026 50

WOK

WORK Medical Technology Group Ltd.Healthcare

$0.66−$0.64

-49.2%

NASDAQ · Mkt cap $5.2 M

WOK dropped 49.23% on May 15, 2026, but no news headlines were available in the prior 48 hours to identify a specific catalyst for the decline.

The absence of recent news headlines makes it impossible to pinpoint a definitive cause for this severe single-day loss. For a micro-cap medical technology stock like WORK, common drivers of this magnitude of decline typically include sudden negative clinical trial results, FDA warning letters or product recalls, unexpected guidance cuts, insider selling announcements, or loss of a major customer or partnership. Less commonly, extreme intraday volatility in thinly traded stocks can reflect technical capitulation, short covering reversals, or delayed market reaction to news released outside the covered window. The stock's current price of $0.66 suggests either a small-cap or distressed security, both categories prone to outsized moves on limited volume. Without access to the actual headline, regulatory filing, or news wire that triggered the move, attributing a specific cause remains speculative.

LNZA

LanzaTech Global, Inc.Industrials

$9.73−$7.42

-43.3%

NASDAQ · Mkt cap $82 M

LanzaTech announced a $20 million registered direct offering of common stock on May 15, which typically triggers sharp sell-offs due to dilution concerns and signals of capital strain, explaining the 43% single-day decline.

The headline from May 15 clearly states that LanzaTech entered into a securities purchase agreement with institutional investors for a $20 million registered direct offering. This type of offering is a known equity dilution event that typically causes immediate and substantial stock price declines, especially in smaller-cap companies. The timing of the announcement during market hours on May 15 aligns precisely with the stock becoming the second-biggest loser of the day, suggesting the market repriced the stock downward upon learning of the dilution. The Q1 2026 earnings announcement on May 14 may have provided context for why capital raising was necessary, though the specific financial results are not detailed in the snippets provided. Registered direct offerings often signal that management either needs cash urgently or believes the stock is undervalued relative to future potential, but either way, existing shareholders face immediate dilution that justifies the sharp repricing.

SLXN

Silexion Therapeutics Ltd.Healthcare

$0.29−$0.21

-42.1%

NASDAQ · Mkt cap $540 K

Silexion announced a $1 million warrant exercise on the same day it reported positive preclinical immunotherapy results, but the massive 42% drop suggests market concern about dilution, cash position, or disconnect between clinical promise and near-term runway despite the positive data.

The company released encouraging preclinical findings for SIL204 in KRAS-driven cancers on May 14, yet the stock plummeted 42% the following day coinciding with a warrant exercise announcement. This counterintuitive move—positive science news coupled with a sharp decline—points to several possible drivers. The $1 million gross proceeds from warrant exercises is modest for a clinical-stage biotech and may signal limited investor appetite or a relatively small warrant pool, raising questions about cash adequacy and burn rate. The timing of the warrant announcement alongside the positive data release could have triggered profit-taking or revealed that despite encouraging preclinical results, the market views the company's financial position, path to trials, or competitive position unfavorably. Alternatively, the warrant exercise may have triggered dilution-sensitive selling. Without guidance, cash balance disclosure, or details on trial timelines and development costs, we cannot pinpoint whether the decline stems primarily from dilution concerns, inadequate funding for the pipeline, or broader skepticism about the company's near-term value creation despite positive early science.

GAMB

Gambling.com Group LimitedConsumer Cyclical

$2.40−$1.74

-42.0%

NASDAQ · Mkt cap $72 M

Gambling.com Group reported flat Q1 revenue and lower profitability with ongoing marketing headwinds from search ranking pressure and regulatory challenges, disappointing investors despite AI and restructuring initiatives.

The earnings headlines from May 14-15 establish that Gambling.com Group delivered materially weak results: flat revenue in Q1 2026 paired with declining profitability. The company cited two specific structural headwinds: persistent marketing pressure tied to search ranking degradation and ongoing regulatory hurdles in key markets. While management highlighted strategic responses including AI deployment and restructuring aimed at productivity gains and global expansion, these forward-looking statements appear insufficient to offset the negative near-term reality of stalled growth and margin compression. The 42% single-day decline suggests the market was either surprised by the severity of revenue flatness or had higher expectations for profitability resilience. The sports data services segment growth was cited but was evidently offset entirely by marketing weakness, indicating the core business momentum is fragile.

CTEV

Claritev CorporationHealthcare

$13.87−$9.60

-40.9%

NYSE · Mkt cap $662 M

No news headlines were available in the last 48 hours, so the cause of the 40.90% drop cannot be determined from public announcements; this magnitude of move typically reflects a major negative catalyst such as earnings miss, regulatory action, or insider selling.

The absence of any recent news headlines in a 40.90% single-day decline is notable and unusual for a ranked top-5 loser. Such a severe move without identifiable public news suggests either a delayed market reaction to older news not captured in the 48-hour window, an after-hours or pre-market announcement not yet indexed by the news feed, or a catalyst that emerged through channels outside traditional financial media such as SEC filings, clinical trial data, or analyst downgrades. For a company called Claritev Corporation, common drivers of moves of this magnitude include clinical setbacks or FDA rejections if biotech-focused, major customer loss or guidance slash if services-oriented, or significant insider selling. Without access to the specific business model or recent filings, the most likely categories are earnings disappointment, regulatory adverse event, or material guidance reduction.

SBFM

Sunshine Biopharma, Inc.Healthcare

$0.28−$0.19

-39.5%

NASDAQ · Mkt cap $4.5 M

No news headlines were found in the last 48 hours to explain the 39.46% drop, so the cause remains unclear without additional information or market context.

Sunshine Biopharma experienced a severe single-day decline of nearly 40% with zero news coverage in the preceding 48 hours on major financial wires. For a small-cap biotech stock trading at $0.28, such sharp moves can stem from several categories: delayed press releases or regulatory announcements that haven't yet reached RSS feeds, technical selling or short-covering reversals in thinly traded securities, sector-wide biotech weakness, or retail trading volatility. Without access to company filings, SEC announcements, or clinical trial updates posted directly to the company website within the snapshot window, we cannot identify a specific catalyst. The absence of news is itself notable for a stock moving this dramatically, suggesting either a lag in news propagation or a non-news driver such as technical factors or private information leakage.

BLNE

Beeline Holdings, Inc.Financial Services

$1.08−$0.67

-38.3%

SOPA

Society Pass IncorporatedCommunication Services

$0.17−$0.11

-38.2%

NASDAQ · Mkt cap $7.7 K

No news about SOPA was provided; the 38% drop likely reflects broader market weakness, a company-specific negative announcement not captured in the feeds, or technical selling in a low-priced microcap stock.

The single headline provided concerns Bitdeer Technologies (BTDR), a cryptocurrency mining company with Q1 earnings results, and is completely unrelated to SOPA, a society and lifestyle platform operator. SOPA's dramatic 38% single-day decline has no identifiable news catalyst in the data supplied. For microcap stocks trading near $0.17, sharp moves often stem from insider selling, secondary offerings, reverse split announcements, regulatory warnings, or simply illiquidity and technical chart breaks. SOPA may have issued guidance or operational news not captured in these feeds, or the move could be part of a sector rotation or short-seller activity. Without company-specific headlines or structural context about SOPA itself, the true driver remains opaque.

ZGM

Zenta Group Company Limited Ordinary SharesIndustrials

$1.65−$0.91

-35.5%

NASDAQ · Mkt cap $35 M

No news headlines were found in the last 48 hours, so the 35.55% drop cannot be directly attributed to a published announcement. The decline may reflect delayed market reaction to earlier news, technical selling, or an undisclosed catalyst.

The absence of recent headlines makes it impossible to identify a specific catalyst for ZGM's sharp 35.55% decline on this date. For a stock trading at $1.65 on NASDAQ, possible explanations include a delayed market reaction to earnings or guidance released outside the 48-hour window, technical breakdown below support levels that triggered stop-loss selling, short-seller activity or negative research reports that may not have appeared in standard financial RSS feeds, insider selling or lockup expiration, or broad sector rotation out of small-cap or microcap equities. Without access to SEC filings, company press releases, or financial media beyond Yahoo Finance RSS, it is not possible to distinguish between these categories of cause.

FCHL

Fitness Champs Holdings Limited Common StockConsumer Defensive

$1.76−$0.92

-34.3%

NASDAQ · Mkt cap $1.5 M

No news headlines were found in the last 48 hours, so the 34% drop cannot be directly attributed to a public announcement. The decline is likely driven by technical selling, a delayed negative catalyst, or broader market sentiment affecting this micro-cap stock.

Yahoo Finance returned zero headlines for Fitness Champs Holdings in the past 48 hours, eliminating the ability to tie this sharp decline to an earnings miss, guidance cut, product recall, regulatory action, or other discrete corporate event. Fitness Champs is a micro-cap equity trading at $1.76, which makes it susceptible to several categories of unmeasured catalysts: undisclosed insider activity, after-hours or OTC trading pressure, a delayed news release that has not yet been indexed by major financial RSS feeds, technical breakdown below a key support level, or forced selling by leveraged investors. Micro-cap stocks can also be targets for short-seller reports or rumor-driven selling that spreads via social media before formal news channels pick it up. Without access to real-time Level 2 quotes, insider filings, or social sentiment data, pinpointing the exact trigger is not possible.

CREG

Smart Powerr Corp.Utilities

$0.48−$0.24

-33.3%

NASDAQ · Mkt cap $499 K

No news headlines were found in the last 48 hours to explain Smart Powerr Corp.'s 33% decline on May 15, 2026, suggesting the move may reflect technical selling, a delayed announcement, or market-wide pressure specific to this micro-cap stock.

Yahoo Finance returned no headlines for Smart Powerr Corp. in the 48 hours preceding this sharp drop, which makes direct attribution impossible. Smart Powerr is a micro-cap stock trading at $0.48, a category highly susceptible to volatility from illiquidity, thin order books, and retail trading patterns independent of fundamental news. The stock could have experienced a coordinated sell-off due to a delayed press release not yet indexed by Yahoo, an earnings miss or guidance cut, insider selling, or simply a reversion after a prior run-up. Alternatively, the move could reflect no company-specific catalyst at all but rather sector rotation out of small-cap renewable or power-tech names. Without headlines or access to the company's recent filings, price history, or real-time order flow, any conclusion would be speculative.

AARD

Aardvark Therapeutics, Inc. Common StockHealthcare

$4.57−$2.16

-32.1%

NASDAQ · Mkt cap $148 M

Aardvark Therapeutics received an FDA clinical hold on its Prader-Willi syndrome drug candidate, forcing the company to unblind late-stage trial data and potentially overhaul its development program, triggering a 32% sell-off.

The news headlines establish that on May 14-15, 2026, Aardvark announced an FDA clinical hold on its lead asset, the HERO and OLE trials for its Prader-Willi treatment. The company stated it will unblind the halted studies to assess next steps, explicitly signaling potential program restructuring. For a clinical-stage biotech, an FDA hold represents a material setback—it stops trial enrollment, raises safety concerns, and creates uncertainty about whether the asset can proceed or in what form. A 32% single-day decline is consistent with the market repricing the probability of success for what was likely the company's lead or only advanced program. The broader healthcare sector decline of 1.1% that day provides minimal additional context; AARD's move far exceeds sector weakness, indicating the news was idiosyncratic and negative to Aardvark specifically.

ZTEK

Zentek Ltd.Healthcare

$0.69−$0.32

-31.7%

NASDAQ · Mkt cap $75 M

Zentek announced a C$15 million brokered offering on May 14, which typically dilutes existing shareholders and triggered the 31.68% single-day decline as the market priced in immediate equity dilution.

On May 14, Zentek disclosed that it entered into an engagement agreement with Red Cloud Securities for a brokered LIFE offering targeting gross proceeds of up to C$15 million. This is a direct capital raise that dilutes existing shareholders' ownership percentage and voting rights. Such offerings are often viewed negatively by markets because they increase share count without a corresponding increase in asset value, reducing earnings per share and book value per share on a mechanical basis. The magnitude of the decline—31.68%—is substantial but not unusual for a micro-cap stock (trading below $1) announcing significant equity dilution. The offering size relative to the company's apparent market capitalization likely magnified the percentage impact. No other news headlines were provided to suggest alternative causes, and the timing of the announcement on May 14 with the largest single-day drop on May 15 aligns directly with the dilution event.

AIIO

Robo.ai Inc.Consumer Cyclical

$4.02−$1.62

-28.7%

NASDAQ · Mkt cap $487 M

Robo.ai announced a new AI video compression platform launch on May 14th, but the stock fell 28.72% the next day, suggesting investors either viewed the news as insufficient, faced a broader market selloff, or reacted to unannounced negative developments not captured in the provided headlines.

The two headlines from May 14th both describe the same positive development: Robo.ai's Neurovia AI subsidiary launched NeuroStream, a new visual data infrastructure platform for AI-native compression and edge computing. On the surface, this is a product advancement that aligns with stated company strategy. However, the 28.72% single-day drop the following day suggests the market's initial reaction was negative or that additional unfavorable information emerged after these headlines were published. It is possible that investor expectations for this launch were higher, that competitive concerns materialized, that the financial impact timeline disappointed, or that a separate negative catalyst (earnings miss, guidance cut, insider selling, or broader sector rotation) occurred but was not captured in the provided Yahoo Finance RSS feed. Without additional news from later on May 15th or details about the company's financial outlook, the exact trigger remains unclear.

ZENA

ZenaTech, Inc.Technology

$1.52−$0.60

-28.3%

NASDAQ · Mkt cap $189 M

ZENA fell 28.3% despite upbeat news on its ZenaDrone 2000 counter-UAS platform advancing to systems integration; the disconnect suggests either broader market headwinds, profit-taking after a prior rally, or market skepticism about near-term monetization and execution risk.

The headline from May 14 is positive: ZenaTech announced that its gas-powered counter-drone platform completed airframe build, entered systems integration, and has flight testing planned for Q3 2026. This represents concrete technical progress toward a stated $20 billion addressable market. However, the stock dropped sharply the same day or shortly after, which is counterintuitive. This disconnect can occur for several reasons. First, the news may have failed to meet market expectations set by prior guidance or analyst calls, meaning the market had already priced in more advanced milestones. Second, given ZENA's micro-cap status and typical micro-cap volatility, the stock may have experienced profit-taking after a prior rally, or the announcement may have triggered tax-loss harvesting. Third, the market may harbor skepticism about the company's path to revenue and profitability despite the technical milestone, or broader sector or macro weakness may be overwhelming individual stock fundamentals. Without prior context on recent price action or insider positioning, this remains ambiguous.

MOBX

Mobix Labs, Inc.Technology

$2.25−$0.86

-27.7%

NASDAQ · Mkt cap $18 M

Mobix Labs announced a rare-earth minerals acquisition and a convertible note amendment with investor rights agreement on May 14, likely triggering a sharp selloff due to dilution concerns and unclear financing terms that spooked investors despite the strategic rationale.

On May 14, Mobix Labs disclosed two major developments: an acquisition of a U.S. rare-earth and critical-minerals company serving defense, and an amendment to its senior secured convertible note coupled with an investor rights agreement with Leviston Resources. While the acquisition itself targets a strategically important sector aligned with national security demand, the simultaneous convertible debt restructuring and investor rights deal typically signal dilutive financing or unfavorable capital structure changes. The headlines provide limited detail on valuation, financing terms, or shareholder impact, leaving investors to infer potential equity dilution. This combination of capital-intensive M&A, debt restructuring, and new investor rights agreements often triggers sell-offs in smaller-cap stocks, as the market discounts future dilution and management concessions required to fund the transaction.

BZAI

Blaize Holdings, Inc.Technology

$1.31−$0.46

-26.0%

NASDAQ · Mkt cap $81 M

Blaize reported Q1 2026 earnings on May 14–15 with a 170% revenue surge and beat on revenue estimates, but posted a significant net loss and cited supply chain constraints on AI server availability, triggering a 26% single-day selloff likely driven by profitability concerns outweighing top-line g…

Blaize released Q1 2026 results showing strong headline revenue growth of 170% and a +1.41% revenue beat versus consensus. However, the company reported a material net loss for the quarter and acknowledged first-quarter revenue shortfall tied to constrained availability of AI servers using high-bandwidth memory, despite reaffirming full-year 2026 revenue targets. The market's sharp sell-off suggests investors are repricing the stock on two fronts: the substantial quarterly loss raises questions about path to profitability even amid strong revenue expansion, and the supply chain constraint signals near-term execution risk that may pressure margins or delay revenue recognition. The positive revenue surprise and forward guidance reaffirmation were apparently insufficient to overcome loss concerns, a common pattern when growth stocks fail to demonstrate improving unit economics alongside top-line expansion.

BCTX

BriaCell Therapeutics Corp.Healthcare

$3.02−$1.03

-25.4%

NASDAQ · Mkt cap $30 M

BriaCell announced pipeline expansion into ovarian cancer and completed manufacturing for prostate cancer candidate, but these positive clinical developments failed to prevent a sharp 25% stock decline, suggesting broader market or company-specific headwinds unrelated to the news.

The headlines released over the past 48 hours describe clinical progress: completion of manufacturing for Bria-PROS+ and announcement of a new ovarian cancer candidate, Bria-OVA+, building on Phase 2 breast cancer success. These are typically viewed as constructive developments for a clinical-stage immunotherapy company. However, the stock fell 25% on the day, ranking among the top losers. This disconnect suggests the decline was not driven by the content of these announcements themselves. Possible explanations include a broader biotech or small-cap selloff, negative sentiment from an earnings call, guidance revision, cash burn concerns, or insider selling not mentioned in these headlines. The timing of positive news paired with heavy selling is unusual and points to either a market-wide correction hitting the sector or undisclosed negative information.

DARE

Daré Bioscience, Inc.Healthcare

$2.17−$0.69

-24.1%

NASDAQ · Mkt cap $16 M

Daré Bioscience reported Q1 2026 results on May 14th with positive clinical trial news and product launch timelines, but the market reaction was sharply negative, likely driven by financial constraints, capital concerns, or disappointment relative to investor expectations despite the operational …

The company announced a second positive DSMB review for Ovaprene Phase 3 trial data, anticipated commencement of DARE to PLAY dispensing, and a summer 2026 commercial launch for Flora Sync LF5. These are operationally positive developments. However, the headline explicitly mentions capital constraints and regulatory hurdles as contextual factors. A 24% single-day drop following earnings typically indicates either significantly worse-than-expected financials, runway concerns, dilutive capital raises announced, or guidance cuts that overshadowed clinical wins. Without access to the full earnings release, the most likely inference is that cash position, burn rate, or required financing announcements created investor concern that outweighed the positive pipeline updates.

CVV

CVD Equipment CorporationIndustrials

$5.20−$1.65

-24.1%

NASDAQ · Mkt cap $56 M

CVD Equipment reported Q1 2026 earnings on May 14-15 showing revenue declines, booking volatility, and strategic divestitures to stabilize the balance sheet, triggering a 24% sell-off as the market repriced the company's near-term growth prospects.

The earnings release and call transcript indicate that CVD Equipment is grappling with material operational headwinds: continued volatility in order rates and a recent decline in bookings within its core CVD Equipment division. Management's disclosure of strategic divestitures signals balance-sheet stress and a pivot away from growth toward financial stabilization. The market appears to have reacted negatively to both the revenue challenge and the implicit signal that management does not expect near-term recovery. The 24% drop is substantial but consistent with a small-cap equipment manufacturer facing demand destruction in a key business segment. Without the full earnings numbers, we cannot determine whether the decline was steeper than expected or whether guidance was reduced, but the headlines establish clear operational deterioration as the primary driver.

FRMM

Forum Markets, IncorporatedTechnology

$3.70−$1.17

-24.0%

LABT

Lakewood-Amedex Biotherapeutics Inc. Common StockHealthcare

$1.50−$0.46

-23.5%

NASDAQ · Mkt cap $3.8 M

No news headlines were published in the last 48 hours, so the 23.47% drop cannot be directly attributed to a disclosed event. The decline likely stems from sector pressure, technical selling, or undisclosed company developments in a micro-cap biotech stock.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot point to a specific catalyst such as clinical trial results, FDA action, financing developments, or management changes. For a micro-cap biotech stock trading at $1.50, typical catalysts include early-stage trial data releases, capital raises at unfavorable terms, insider selling, sector rotation out of unprofitable therapeutics companies, or broader market pressure on high-risk equities. The sharp single-day decline of nearly a quarter of the stock's value is consistent with either a sudden negative development that has not yet been widely reported, technical breakdown in thin trading, or preannouncement positioning ahead of news. Without access to company press releases, SEC filings, or social media, the true driver remains opaque.

CGTL

Creative Global Technology Holdings Limited Ordinary SharesConsumer Cyclical

$0.50−$0.15

-23.2%

NASDAQ · Mkt cap $8.2 M

No news headlines were available in the last 48 hours to explain CGTL's 23.21% decline, making the specific catalyst unclear without additional reporting.

Yahoo Finance returned zero headlines for CGTL in the most recent two days, which prevents direct attribution of the stock's sharp 23.21% drop to any announced event such as earnings, guidance, regulatory action, or corporate news. For a microcap stock trading at $0.50, typical catalysts for large single-day declines include delayed financial filings, unannounced insider selling, short-squeeze reversals, technical breakdown through support levels, or off-exchange news (social media, chat forums, or press releases not yet picked up by major RSS feeds). Without confirmed reporting, the cause remains speculative. The stock's low price and rank as the 23rd biggest loser suggests it may be volatile or subject to retail trading activity that can amplify moves independent of fundamental news.

CAST

FreeCast, Inc. Class A Common StockCommunication Services

$1.44−$0.42

-22.6%

NASDAQ · Mkt cap $100 M

No news headlines were found in the last 48 hours, so the 22.58% drop cannot be attributed to a specific announced event; it may reflect market sentiment, technical selling, or undisclosed developments.

The absence of recent news headlines makes it impossible to point to a specific catalyst for CAST's sharp 22.58% decline. FreeCast is a micro-cap stock trading near $1.44, which typically exhibits higher volatility and can be more susceptible to thin trading volume, technical breakdowns, or shifts in investor sentiment that may not generate immediate news coverage. The drop could reflect selling pressure from several possible sources: deteriorating fundamentals revealed in recent earnings or filings not yet indexed by news aggregators, loss of investor confidence, reduction in trading liquidity, or broader sector weakness in digital media or streaming. Without access to recent press releases, SEC filings, or trading volume data, we cannot distinguish between these categories.

POET

POET Technologies Inc.Technology

$15.97−$4.60

-22.4%

NASDAQ · Mkt cap $1.5 B

POET fell 22.36% after reporting Q1 earnings that missed expectations and announcing a $400 million dilutive registered direct offering, reversing gains from the prior day's $500 million supply deal announcement.

The evidence establishes two concrete negative catalysts on May 15. First, POET reported first quarter 2026 financial results that came in below expectations, with only $503,000 in quarterly revenue mentioned in one headline as context for the company's valuation. Second, the company announced a $400 million registered direct offering of common shares and warrants, a classic dilutive financing that pressures stock price through immediate share dilution and signals management views the stock as overvalued at current levels. The stock had surged 114.72% in the week prior on enthusiasm around the $500 million Lumilens supply deal announced on May 14, but that momentum reversed sharply when the weaker earnings and dilutive capital raise became public. The headlines also note executive leadership changes were announced alongside the financing. Broader market weakness in Nasdaq sentiment that day provides marginal context but the stock-specific news dominates the move.

PLYX

Polaryx Therapeutics, Inc. Common StockHealthcare

$2.67−$0.74

-21.7%

NASDAQ · Mkt cap $105 M

Polaryx fell 21.7% despite receiving industry recognition awards on May 14th, suggesting the drop was driven by factors unrelated to the positive headline, such as broader market weakness, a separate negative catalyst, or profit-taking in a volatile biotech stock.

The only recent news provided is a positive industry award announcement from GHP Magazine recognizing Polaryx as a leader in pediatric lysosomal storage disease and rare neurodegenerative disease drug development. This accolade typically supports stock sentiment rather than triggering a sharp decline. The magnitude and timing of the 21.7% drop on May 15th—the day after the award was announced—suggests the sell-off was either unrelated to this news or caused by a separate catalyst not captured in the headlines provided. Biotech stocks are volatile and commonly react to clinical trial results, FDA decisions, funding announcements, or broader sector headwinds. Without additional reporting, it is unclear whether Polaryx experienced an adverse clinical or regulatory event, guidance revision, or simply tracked downward momentum in the biotech sector.

ARTL

Artelo Biosciences, Inc.Healthcare

$1.84−$0.50

-21.4%

NASDAQ · Mkt cap $3.3 M

Artelo reported Q1 2026 results and a business update with upcoming milestones on May 14, but the stock fell 21.37% the next day, suggesting investors reacted negatively to the financial results or guidance despite the company's claim of a strengthened balance sheet and advancing pipeline.

The headline describes a business update and Q1 2026 financial results released after market close on May 14. The company emphasized a strengthened balance sheet and multiple clinical catalysts expected through 2027, which would typically be framed as positive. However, the sharp 21% decline the following day indicates the market interpreted something in the full earnings release unfavorably. Possible explanations include: disappointing cash burn rates or cash runway shorter than expected, lower-than-anticipated cash position despite the "strengthened balance sheet" claim, missed clinical trial milestones or delayed timelines, weaker-than-expected operational metrics, or revised guidance. Without access to the complete earnings release details, we cannot determine which specific metric or guidance drove the selloff. For early-stage biotech firms like Artelo, negative reactions to financial results or pipeline delays are common catalysts.

HKIT

Hitek Global Inc.Technology

$0.69−$0.19

-21.3%

NASDAQ · Mkt cap $27 M

No news headlines were found in the last 48 hours, so the 21% drop cannot be attributed to any identified announcement or event. The decline likely stems from technical selling, delayed negative developments, or sector-wide pressure affecting this micro-cap stock.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to point to a specific catalyst for HKIT's sharp 21% decline. Hitek Global is a micro-cap security trading below $1, which typically means lower analyst coverage, wider bid-ask spreads, and higher sensitivity to technical factors and sentiment shifts. For stocks in this category, price swings of this magnitude can occur due to algorithmic selling, margin calls affecting holders, accumulation of bad news released on less-monitored channels (company filings, Twitter, investor forums), or simple lack of liquidity triggering cascading exits. Without headlines or recent earnings/guidance data, we cannot distinguish between these possibilities. It is also possible that negative news was released before the snapshot date but fell outside the 48-hour window.

CODX

Co-Diagnostics, Inc.Healthcare

$1.29−$0.35

-21.2%

NASDAQ · Mkt cap $6.9 M

Co-Diagnostics reported Q1 2026 earnings today showing progress in diagnostics development but facing revenue growth and profitability challenges, triggering a 21% sell-off likely driven by investor disappointment with financial performance.

Co-Diagnostics released Q1 2026 financial results on May 15, 2026, and the headlines consistently emphasize a mixed picture: the company made strategic advances and progress in diagnostic test development and clinical evaluations, but simultaneously reported revenue growth hurdles and ongoing profitability challenges. The earnings call highlights specifically note financial headwinds despite technological progress. For a small-cap diagnostic company trading at $1.29, this combination of missed or disappointing revenue expectations with continued losses appears to have triggered sharp selling pressure. Investors likely reacted to evidence that operational progress has not yet translated to meaningful top-line or bottom-line improvement, raising questions about the company's path to profitability and cash runway.

GDXU

MicroSectors Gold Miners 3X Leveraged ETNFinancial Services

$157.47−$42.18

-21.1%

AMEX

No news headlines were found in the last 48 hours to explain the 21% decline, but GDXU is a 3X leveraged gold mining ETN that amplifies daily moves in its underlying index, so a sharp drop in gold miners or gold prices would mechanically trigger this magnitude of loss.

No recent news articles are available to identify a specific catalyst for today's move. However, GDXU's structure provides a clear framework for understanding the decline. As a 3X leveraged exchange-traded note tracking gold miners, it amplifies daily price movements in its underlying index by three times. A sustained sell-off in the gold mining sector or a decline in gold prices themselves would mechanically produce losses of this magnitude. Gold mining equities and precious metals are sensitive to macro factors including real interest rate expectations, US dollar strength, inflation data, and investor risk appetite. Without specific news provided, the most probable categories of cause are either a macroeconomic shift affecting the gold complex, a negative technical breakdown in gold or mining stocks, or delayed market reaction to earlier announcements not captured in the 48-hour window.

DXF

Eason Technology LimitedFinancial Services

$1.39−$0.36

-20.6%

AMEX · Mkt cap $1.6 M

DXF fell 20.57% on Friday as Asian ADRs traded sharply lower, following a broader reversal from Thursday's gains in the same sector without company-specific news disclosed.

The headlines provided reference only broad sector movements in Asian equities trading as American depositary receipts, noting that Friday saw sharp declines after Thursday saw gains. No company-specific news, earnings, guidance, regulatory action, or material announcements about Eason Technology Limited appear in the provided headlines. The timing and magnitude of the decline suggest DXF moved with broader ADR weakness rather than idiosyncratic company news. Stocks like DXF, which trade on smaller exchanges and represent foreign equities, typically respond to sector rotation, currency fluctuations, geopolitical developments affecting Asia, or shifts in capital flows to emerging markets. Without company specifics, the drop appears driven by macro headwinds affecting the ADR space generally on Friday morning.

AMZE

Amaze Holdings, Inc.Technology

$0.17−$0.04

-20.5%

AMEX · Mkt cap $1.5 M

No news headlines were found in the last 48 hours to explain the 20.47% drop in AMZE stock, suggesting the decline was likely driven by technical selling, low-volume volatility typical of penny stocks, or undisclosed company developments.

The absence of any news coverage in the past 48 hours makes it difficult to pinpoint a specific catalyst for AMZE's sharp decline. Stocks trading at $0.17 on the AMEX are typically thinly traded microcap or penny stocks, which are prone to large percentage swings on minimal volume and can react to factors that do not generate mainstream financial news—such as insider selling, failed product launches, regulatory setbacks at the subsidiary level, delayed financing, or negative social media discussion among retail traders. Without access to press releases, SEC filings, or company announcements, we cannot determine whether the decline reflects a concrete business event or is primarily a function of low liquidity and technical momentum. The stock's rank as the 32nd biggest loser suggests broad market stress or a sector-wide selloff is unlikely to be the main driver.

AEHL

Antelope Enterprise Holdings LimitedIndustrials

$3.61−$0.92

-20.3%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours for AEHL, so the 20% drop cannot be directly attributed to a specific announced event; it may reflect a delayed market reaction, technical selling, or undisclosed company developments.

The absence of recent news headlines means the drop cannot be tied to a named catalyst such as earnings, guidance, regulatory action, or M&A activity. For a micro-cap stock like AEHL trading at $3.61, a 20% single-day move without accompanying news typically reflects one of several patterns: delayed reaction to an earlier announcement that markets are only now pricing in, liquidity-driven technical selling triggered by a break of a key support level, or reaction to company developments or rumors not yet captured in major financial news feeds. Micro-cap equities are also more susceptible to sentiment shifts and institutional rebalancing. Without access to SEC filings, earnings releases, company press releases, or investor communications issued in the past 48 hours, it is impossible to determine whether the move is fundamentally driven or purely technical in nature.

INUV

Inuvo, Inc.Technology

$1.54−$0.39

-20.2%

RCMT

RCM Technologies, Inc.Industrials

$23.12−$5.84

-20.2%

NASDAQ · Mkt cap $286 M

RCMT dropped 20% with no news headlines in the last 48 hours, suggesting either a delayed market reaction to an earlier announcement, internal corporate event, or broad sector pressure not yet captured in available feeds.

No headlines were available in the last 48 hours to establish a specific catalyst for the 20% decline. RCM Technologies is a staffing and IT services provider, a sector that can be sensitive to contract wins, losses, guidance revisions, or macroeconomic shifts in hiring demand. The magnitude of the move on zero visible news suggests either a significant event occurred outside the headline window captured here, the market is reacting to technical factors or options expiration, or an announcement was made through channels not yet reflected in standard financial news feeds. Without corroborating headlines or structural context about RCMT's current situation, the true driver remains unclear.

RXT

Rackspace Technology, Inc.Technology

$5.82−$1.47

-20.2%

NASDAQ · Mkt cap $839 M

No news headlines were found in the last 48 hours, so the 20% decline in RXT cannot be directly attributed to a disclosed event; the move likely reflects either delayed market reaction to an earlier announcement, technical selling, or broad sector weakness in cloud infrastructure stocks.

Rackspace Technology experienced a sharp single-day loss of over 20%, ranking it among the day's largest losers, yet no relevant news appears in the 48-hour window provided. This disconnect suggests either that the catalyst predates the snapshot window, that the market is reacting to a rumor or analyst downgrade not captured in the headlines supplied, or that the stock is experiencing technical or momentum-driven selling. For a managed cloud services and infrastructure provider like RXT, typical catalysts would include quarterly earnings misses, guidance reductions, customer churn announcements, competitive pressure from AWS or Microsoft Azure, or macroeconomic concerns about enterprise IT spending. Without specific news, the trigger remains speculative, though the magnitude of the move suggests something material rather than pure technical action.

Visionary Holdings Inc.Consumer Defensive

$0.24−$0.06

-20.1%

NASDAQ · Mkt cap $157 K

No news headlines were available in the last 48 hours, so the 20% intraday drop cannot be tied to a specific announced event. The move is likely driven by technical selling, sector weakness, or undisclosed company developments.

The absence of recent news makes it impossible to identify a concrete catalyst for the sharp 20% decline in GV stock. Penny stocks and micro-cap equities like GV are particularly sensitive to momentum shifts, short-covering reversals, and technical support breaks that may not correlate with headline announcements. Common drivers for moves in this segment include dilutive financing announcements, insider selling, failed clinical or product milestones, regulatory setbacks, or broad delisting risk warnings that may circulate on message boards before formal disclosure. Without access to SEC filings, company statements, or verified news from the snapshot date itself, attribution remains speculative. The stock's position as the 37th biggest loser suggests sector-wide or market-wide pressure may also be a factor.

CURI

CuriosityStream Inc.Communication Services

$2.52−$0.61

-19.5%

NASDAQ · Mkt cap $173 M

CuriosityStream missed Q1 revenue estimates by 11.37% and reported a quarterly loss, offsetting positive gross margin improvement and a dividend raise, triggering a sharp 19.5% sell-off driven by subscriber and revenue stream challenges acknowledged in the earnings call.

The stock's 19.49% decline aligns directly with the company's Q1 2026 earnings results released on May 14-15. While CuriosityStream achieved modest year-over-year revenue growth to $15.2 million, it fell 11.37% short of analyst expectations and reported a net loss for the quarter. The company did report a 56% gross margin, up from 53% in the prior year, and raised its quarterly dividend to $0.085. However, these positive metrics were overshadowed by the earnings miss and management's acknowledgment of "subscriber and revenue stream challenges." The headlines also note the company is prioritizing artificial intelligence dataset licensing opportunities, suggesting a strategic pivot. Investors appear to have punished the revenue miss and operational headwinds more heavily than they rewarded the margin improvement and dividend increase, a common pattern when growth falters at smaller-cap companies.

WYFI

WhiteFiber, Inc. Ordinary SharesTechnology

$24.20−$5.79

-19.3%

NASDAQ · Mkt cap $730 M

WhiteFiber reported strong Q1 revenue growth of 31% and positive adjusted EBITDA, but swung to a $12 million net loss and continues to burn cash on infrastructure buildout, disappointing investors despite operational progress.

WhiteFiber released Q1 2026 earnings on May 14-15, posting 31% year-over-year revenue growth to $21.9 million and achieving positive adjusted EBITDA—typically bullish signals. However, the company posted a $12 million net loss and is in the midst of heavy capital expenditure for its NC1 data center project in North Carolina and broader AI/HPC infrastructure expansion. The headlines acknowledge net losses and supply chain hurdles as headwinds. The 19% decline suggests the market weighted the cash burn and path to profitability more heavily than the top-line growth and adjusted profitability metrics. Investors may also be concerned about the competitive intensity in AI infrastructure or the timing and costs of completing major projects. The headlines do not indicate any negative guidance or project delays, so the sell-off appears driven by the operating loss reality outweighing growth headlines.

IONX

Daily Target 2X Long IONQ ETF

$56.56−$13.42

-19.2%

NASDAQ

No news headlines were found in the last 48 hours, but IONX is a 2X leveraged ETF tracking IONQ, so a significant decline in the underlying quantum computing stock would be amplified roughly twofold in the fund's price action.

The absence of any news in the last 48 hours makes it impossible to identify a specific catalyst from headline evidence. However, IONX's structure as a daily target 2X long leveraged ETF is highly relevant context. A 19.18% drop in a leveraged fund of this magnitude typically reflects either a sharp move in the underlying IONQ stock (roughly 9-10% decline would produce a 2X amplified move), decay from volatility drag in a leveraged instrument, or both. Quantum computing stocks are inherently volatile and sentiment-driven assets that can swing sharply on technical factors, sector rotation, or delayed news dissemination. Without specific headlines provided, the cause cannot be attributed to company-specific news, but rather reflects either underlying IONQ weakness or broader quantum computing sector headwinds on this particular trading day.

IONL

GraniteShares 2x Long IONQ Daily ETF

$29.71−$7.03

-19.1%

NASDAQ

No news headlines were published in the last 48 hours, but the 19.13% decline in this 2x leveraged IONQ ETF likely reflects a sharp drop in the underlying IonQ stock, which would be amplified roughly twofold by the fund's daily leverage mechanism.

The absence of recent news headlines makes direct attribution impossible. However, IONL is a 2x long leveraged daily ETF tracking IonQ, a quantum computing company. A nearly 20% drop in a 2x leveraged fund implies roughly a 9-10% decline in the underlying stock price. Leveraged ETFs amplify daily moves in their tracking stock, so any significant adverse price action in IonQ shares would mechanically produce an exaggerated loss in IONL. Without headlines, the cause in IonQ could range from broad quantum sector weakness, profit-taking after recent gains, technical selling, market-wide equity pressure, or undisclosed company-specific news not yet reflected in financial media. Quantum stocks are volatile and sentiment-driven, making them susceptible to momentum reversals without necessarily requiring published catalysts.

BFRI

Biofrontera Inc.Healthcare

$0.80−$0.19

-19.1%

NASDAQ · Mkt cap $21 M

Biofrontera reported Q1 earnings on May 14 that beat revenue expectations but posted a significant net loss, triggering a 19% sell-off despite revenue growth, likely due to investor disappointment with profitability and unspecified regulatory uncertainties.

The headlines establish that Biofrontera delivered a 6.15% revenue beat and reported 17% year-over-year revenue growth in Q1 2026. However, the company posted a net loss with an earnings surprise of -127.78%, meaning results fell sharply short of profit expectations. The earnings call summary references "navigating increased expenses and regulatory uncertainties" without detailing specifics, which may have amplified sell-side concern. For a small-cap biopharmaceutical company, profitability remains critical to investor confidence; top-line growth alone does not offset operating losses and undefined regulatory headwinds. The timing of the 19% decline immediately following the May 14 earnings release strongly suggests earnings disappointment and forward guidance concerns drove the move rather than any other catalyst.

BMNG

Leverage Shares 2x Long BMNR Daily ETF

$22.62−$5.33

-19.1%

NASDAQ

No news headlines were published in the last 48 hours, but BMNG is a 2x leveraged long ETF tracking BMNR, so a roughly 9.5% decline in the underlying would mechanically produce this 19% drop through leverage amplification.

The absence of recent news headlines makes direct causation impossible to establish from the provided information. However, BMNG is a leveraged ETF designed to deliver twice the daily return of its underlying index or asset BMNR. A 19% single-day loss in a 2x long product is consistent with approximately a 9.5% decline in the underlying security or benchmark. This suggests the move is driven by whatever caused BMNR itself to fall sharply today, not by any news specific to the ETF wrapper itself. Without knowing what triggered BMNR's decline, the most likely categories are broad market selloff, sector rotation, or asset-specific negative developments in BMNR's holdings or strategy. The leverage simply amplifies the underlying directional move.

TXXS

21Shares 2x Long Sui ETF

$5.85−$1.38

-19.0%

NASDAQ

No relevant news headlines were found in the last 48 hours, but the 19% single-day drop in this 2x leveraged Sui ETF likely reflects a sharp decline in the underlying Sui cryptocurrency or broader crypto market weakness.

TXXS is a 2x long leveraged ETF tracking Sui, a blockchain asset. No news was published in the past 48 hours according to the provided feed, so the price collapse was not driven by a company-specific announcement or earnings event. However, leveraged cryptocurrency ETFs are highly sensitive to moves in their underlying assets. A 19% drop in a 2x long product suggests the underlying Sui token fell roughly 9.5-10% on the day, which is plausible during crypto market volatility. Leverage amplifies both gains and losses, so even moderate downward pressure on Sui would translate into significant ETF losses. Without access to Sui's price data or broader crypto market news from the same window, the exact trigger remains unknown, but it was almost certainly external to the ETF itself and rooted in cryptocurrency market conditions.

BLSG

Leverage Shares 2x Long BLSH Daily ETF

$4.40−$1.03

-18.9%

NASDAQ

No news headlines were found in the last 48 hours, so the 18.92% drop likely reflects a sharp decline in the underlying BLSH security that this 2x leveraged ETF amplifies.

BLSG is a 2x daily leverage ETF tracking BLSH, which means it is designed to deliver twice the daily return of its underlying benchmark. With no news reported in the past 48 hours to explain a move of this magnitude, the most probable cause is a significant decline in BLSH itself, which would be amplified to roughly double in this leveraged product. Leveraged ETFs are particularly sensitive to sharp moves in their underlying index or security, and decay can occur over longer holding periods, but a single-day 18.92% drop is most consistent with a substantial underlying move rather than structural decay. Without headlines about BLSH or its components, we cannot identify the specific catalyst, but the mechanism is mechanical: if BLSH fell approximately 9-10% on the day, BLSG would fall roughly twice that in the daily reset structure.

QTI

QT Imaging Holdings, Inc.Healthcare

$5.45−$1.26

-18.8%

IRE

Daily Target 2X Long IREN ETF

$26.73−$6.17

-18.8%

AMEX

No news headlines were found in the last 48 hours, but IRE is a 2X leveraged ETF tracking IREN; a roughly 9-10% drop in the underlying stock would amplify to an 18% loss, suggesting weakness in the underlying renewable energy company or sector.

No recent news was available on Yahoo Finance in the 48-hour window, so the cause cannot be attributed to a specific announced event. However, IRE's structure as a daily target 2X long leveraged ETF is material context. Leveraged ETFs amplify both gains and losses of their underlying asset on a daily basis. A decline of approximately 9-10% in IREN (the underlying stock) would mechanically produce roughly an 18-20% loss in IRE due to the 2X multiplier. This does not explain what caused IREN itself to fall, which could stem from sector rotation, earnings disappointment, broader market weakness on May 15, 2026, a company-specific announcement not yet indexed in the RSS feed, or technical selling. Without headlines or news visibility, the proximate cause of IREN's weakness remains unclear.

FSHPR

Flag Ship Acquisition Corporation

$0.08−$0.02

-18.7%

NASDAQ

No news headlines were available in the last 48 hours to explain the 18.72% drop in FSHPR, so the cause remains unclear without additional context or market data.

Flag Ship Acquisition Corporation is a blank-check acquisition vehicle (SPAC), and no recent news headlines were found to account for today's sharp 18.72% decline. SPACs are particularly sensitive to shifts in investor sentiment, changes in deal terms or timeline, management departures, or broader market conditions affecting blank-check vehicles. The stock's very low price of $0.08 suggests it may already be trading near cash value or dissolution value, which is typical for SPACs late in their lifecycle or facing uncertainty. Without headlines, the decline could reflect delayed announcements about a failed or delayed merger, insider selling, regulatory developments, or simply reduced trading volume amplifying normal price movements in a thinly traded security.

IREG

Leverage Shares 2x Long IREN Daily ETF

$20.10−$4.56

-18.5%

NASDAQ

No news headlines were found in the last 48 hours, but IREG is a 2x leveraged long ETF on IREN, so a roughly 9% drop in the underlying would produce this 18% decline; the underlying stock likely fell sharply due to undisclosed company-specific or market conditions.

IREG is a daily leveraged ETF that amplifies the daily returns of its underlying IREN security by a factor of two. With an 18.49% decline in IREG, this implies the underlying IREN stock fell approximately 9% on the day. No news headlines were provided to identify a specific catalyst for that underlying move. However, leveraged ETFs of this type typically decline when their underlying stocks face negative catalysts such as earnings misses, negative guidance, sector weakness, or technical selling pressure. Without headlines or access to IREN's news, the precise cause of the 9% underlying move cannot be determined. The absence of any Yahoo Finance headlines in the 48-hour window is notable but does not prove no news was released; it may indicate limited newswire coverage or that the move was driven by technical factors, market-wide pressure, or company-specific events not captured in syndicated feeds.

KORU

Direxion Daily MSCI South Korea Bull 3X ETF

$751.34−$168.54

-18.3%

AMEX

No news headlines were found in the last 48 hours to explain the 18.32% decline, but KORU is a 3X leveraged ETF tracking South Korean equities, so a sharp move in the underlying index would be magnified proportionally into this drop.

The absence of any headlines in the search results means there is no identifiable company-specific, market-structure, or geopolitical news event on record for the past two days. However, KORU's structure provides a clear explanation pathway. As a Direxion Daily MSCI South Korea Bull 3X ETF, it uses leverage to deliver three times the daily return of its underlying index. A roughly 6% decline in the MSCI South Korea index would naturally translate into an 18% drop in KORU due to the 3X multiplier. The real catalyst therefore lies not in KORU itself but in whatever moved South Korean equities sharply lower over the past 48 hours—whether broad market weakness, currency depreciation, sector headwinds, geopolitical tension, or other macro factors affecting Korea. Without headlines or index data provided, we cannot pinpoint the root cause, but the ETF's leverage mechanically amplifies whatever direction the underlying took.